Grant: Operating Grant - E-Rare-2 Joint Transnational Call on Rare Diseases
McGill University
$100,000.00
Dysregulation of RNA in the pathogenesis of ALS
EF 2013-14
Résumé
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease) is a fatal neurodegenerative disorder characterized by the loss of certain neurons that relay messages from the brain to skeletal muscles. The result is gradual loss of the ability to move, to swallow, to speak and eventually to breathe. ALS is classified as a rare disorder, but the devastation of this disease impacts well beyond the patient to families and the community. Studies in both familial and sporadic forms of ALS are pointing to abnormalities of RNA processing being a key common mechanism of pathogenesis. The cell produces multiple forms of RNAl. Messenger RNA (mRNA) is the template of DNA used to make proteins. RNA-binding proteins, several of which are mutated in ALS, complex with mRNAs to transport them out of the nucleus to make proteins where they are needed. Whether that protein gets made also depends on the stability of the mRNA template, which is regulated by microRNAs (miRNA). Members of our team are identifying changes in expression of these miRNAs in ALS neurons with significant impact on production of neurofilament proteins and their assembly into filaments (neurofilaments) that support the cellular architecture and several important processes of cellular homeostasis and response to stress. Our consortium will determine how dysregulation of miRNAs contribute to multiple forms of ALS and model these changes in tissue culture and animal models to use for preclinical therapeutic investigation. Although the mechanisms involved in dysfunction and loss of neurons in ALS are complex, we expect our work will show that neurofilament regulation is important and can be used as a representative measure of outcome for developing and testing therapies.
Programme
Operating Grant - E-Rare-2 Joint Transnational Call on Rare Diseases
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
288519
Name
Durham Heather D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Israeli Ministry of Health; Fonds de recherche du Québec - Santé (FRQS); Amyotrophic Lateral Sclerosis Society of Canada; The French National Research Agency (France)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Dysregulation of RNA in the pathogenesis of ALS
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - E-Rare-2 Joint Transnational Call on Rare Diseases
Keyworddelim
Amyotrophic Lateral Sclerosis; Microrna; Neurofilaments; Pathogenesis; Preclinical Models; Rna
Abstract
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease) is a fatal neurodegenerative disorder characterized by the loss of certain neurons that relay messages from the brain to skeletal muscles. The result is gradual loss of the ability to move, to swallow, to speak and eventually to breathe. ALS is classified as a rare disorder, but the devastation of this disease impacts well beyond the patient to families and the community. Studies in both familial and sporadic forms of ALS are pointing to abnormalities of RNA processing being a key common mechanism of pathogenesis. The cell produces multiple forms of RNAl. Messenger RNA (mRNA) is the template of DNA used to make proteins. RNA-binding proteins, several of which are mutated in ALS, complex with mRNAs to transport them out of the nucleus to make proteins where they are needed. Whether that protein gets made also depends on the stability of the mRNA template, which is regulated by microRNAs (miRNA). Members of our team are identifying changes in expression of these miRNAs in ALS neurons with significant impact on production of neurofilament proteins and their assembly into filaments (neurofilaments) that support the cellular architecture and several important processes of cellular homeostasis and response to stress. Our consortium will determine how dysregulation of miRNAs contribute to multiple forms of ALS and model these changes in tissue culture and animal models to use for preclinical therapeutic investigation. Although the mechanisms involved in dysfunction and loss of neurons in ALS are complex, we expect our work will show that neurofilament regulation is important and can be used as a representative measure of outcome for developing and testing therapies.
Competitiondate
201305
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Durham, Heather D
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $100,000~ $0~